INTRODUCTION
============

According to the recently published report of the Korea National Health and Nutritional Examination Survey 2011, which is a cross-sectional health surveillance program on a nationwide scale, 4 million Koreans aged 30 years or older have diabetes, and the prevalence of diabetes was 12.4% \[[@B1][@B2]\]. In 2016, diabetes was ranked as the sixth cause of death and the most common cause of renal replacement therapy in Korea \[[@B3][@B4]\]. According to the annual report on Health Insurance Statistics by the Korean National Health Insurance Service (NHIS) and the Korean Health Insurance Review & Assessment (KHIRA) Service, diabetes ranked third in medical expenses as a single disease in Korea in 2015 \[[@B1]\].

The systematic care for chronic illnesses with large socioeconomic and health burdens such as type 2 diabetes mellitus (T2DM) is a very important health issue. For the establishment of management policies and improvement in the quality of care of this chronic metabolic disease, an accurate analysis of the current nationwide database (DB) on health information would be an initial step. The Korean NHIS program covers the computerized DB containing all of the claim data, including patient demographics, drug prescriptions, diagnostic codes for the disease coding system, the International Classification of Diseases (ICD), insurers\' payment coverage, patients\' deduction, and claimed treatment details \[[@B5][@B6]\]. The NHIS DB represents the entire Korean population; therefore, it can be used in a population-based nationwide study for T2DM in Korea.

SOURCE OF DATABASE AND DEFINITION OF T2DM
=========================================

Among the total datasets of the NHIS DB, we used qualifications, claims, the health check-up DB, and death information. The claim DB consists of four categories, including general information on specifications, consultation statements, diagnosis statements classified by the International Classification of Diseases 10th revision (ICD-10), and detailed information about prescriptions \[[@B5][@B6][@B7]\]. To extract the health information of the general population, we used the DB from the general health check-up. Due to the inevitable limitations of the claim DB, T2DM and related diseases were defined operationally ([Table 1](#T1){ref-type="table"}). To validate the information accuracy, an expert committee from the Korean Diabetes Association (KDA) reviewed the DB regularly during this analysis. The committee decided the suitability of the dataset and reviewed the results of the analysis.

Among all of the beneficiaries of the NHIS, retrospective data for adult patients with T2DM aged 30 years or older were extracted from January 2002 through December 2013. Patients were classified as having T2DM when they had at least one service claim with a diagnosis of T2DM based on ICD-10 codes E11, E12, E13, or E14, as either the principal diagnosis or the first to fourth additional diagnosis, and were prescribed at least one antidiabetic drug anytime in a given year to exclude prediabetes or non-diabetic subjects \[[@B7]\]. Type 1 diabetes mellitus, gestational diabetes, and subjects with missing data were excluded. All of the ambulatory visits and any reason for hospitalizations with ICD-10 codes of T2DM were included. Using the national health examination DB, subjects with fasting blood glucose levels ≥126 mg/dL without a claim for antidiabetic medication under the ICD-10 code (undiagnosed diabetes) were also considered as having diabetes. This study was approved by the Institutional Review Board of the Korean National Institute for Bioethics Policy (P01-201504-21-005). Informed consent was exempted by the board.

From this analytical process, the prevalence of T2DM based on the claim DB, trends in diabetic complications and the prescription patterns of antidiabetic drugs, and depression in Korean adult patients with T2DM are summarized in this report.

PREVALENCE AND INCIDENCE OF T2DM
================================

We defined T2DM by the NHIS claim DB only if the subjects had visited a healthcare institution and had antidiabetic medications or by the health check-up DB if they showed high fasting glucose levels (≥126 mg/dL) without a claim for antidiabetic medication under the ICD-10 code of T2DM ([Table 1](#T1){ref-type="table"}). Based on this claim DB, the prevalence of T2DM increased 0.2% to 0.5% annually, from 5.6% (1,655,495 patients) in 2006 to 8.0% (2,720,777 patients) in 2013 \[[@B8]\]. The incidence of T2DM was 0.81% in 2013 and increased with age \[[@B8]\]. The incidence of T2DM was 1.4 times higher in men than in women ([Table 2](#T2){ref-type="table"}). The prevalence of impaired fasting glucose (glucose levels of 100 to 125 mg/dL without antidiabetic medications or an ICD-10 code of T2DM in the health check-up DB) increased from 21.5% in 2006 to 25.0% in 2013 ([Table 2](#T2){ref-type="table"}).

In addition, hypertension (62.5% vs. 16.9%) and dyslipidemia (45.9% vs. 9.7%) were more prevalent in patients with T2DM than in non-diabetic adults, respectively. In contrast, the control rate of hypertension from the health check-up DB was significantly lower in patients with T2DM compared to non-diabetic subjects (75.8% vs. 87.1%, *P*\<0.001) \[[@B8]\].

CHANGES IN PRESCRIPTION PATTERNS OF ANTIDIABETIC MEDICATIONS
============================================================

We analyzed the trends in the prescription patterns of antidiabetic agents in T2DM, such as sulfonylurea (SU), metformin, α-glucosidase inhibitor, meglitinide, dipeptidyl peptidase-4 (DPP-4) inhibitor, thiazolidinedione, and insulin. Sodium-glucose co-transporter-2 inhibitor, which was introduced in 2015, and glucagon-like peptide-1 receptor agonist, which had limited insurance coverage, were not included in the analysis.

Among 870,000 patients with T2DM who were treated with antidiabetic agents, SU was the most commonly used (87.2%), and metformin held the next rank (52.9%) in 2002 \[[@B7]\]. During the past decade, the use of metformin increased steadily to 80.4% of total antidiabetic drug prescriptions and was the most frequently prescribed antidiabetic agent in Korea in 2013. The Clinical Practice Guidelines of the KDA recommend that active lifestyle modification and the appropriate use of antidiabetic agents are needed following the initial diagnosis of T2DM. Metformin is the preferred initial oral antidiabetic agent \[[@B9][@B10]\]. Therefore, the proportion of metformin use is expected to be maintained constant at the current level.

Since the introduction of DPP-4 inhibitors in Korea at the end of 2008, its use has increased dramatically, comprising one-third of the Korean market share (38.4%) in 2013. The prescription of insulin increased to 19.1% of all patients with T2DM in 2008 and then was maintained as a constant over time ([Table 3](#T3){ref-type="table"}) \[[@B7]\].

Among antidiabetic prescriptions, the proportion of monotherapy declined from 58.4% in 2002 to 39.5% in 2013 \[[@B7]\]. In contrast, dual and triple combination therapy steadily increased from 35.0% and 6.6% in 2002 to 44.9% and 15.5% in 2013, respectively (*P* for trend \<0.0001) \[[@B7]\]. In 2002, SU with metformin was the most frequently used dual therapy combination (68.7%). However, in 2013, SU with metformin (41.7%) and metformin with DPP-4 inhibitors (32.5%) dual combination therapies were the most frequently prescribed. According to the increased number of patients with T2DM, total antidiabetic pharmacy expenditures dramatically increased from 83 billion won in 2002 to 582 billion won in 2013 \[[@B7]\]. In addition, the mean payment per patient per year for antidiabetic medication was about 90,000 won in 2002 and 180,000 won in 2013.

DIABETIC RETINOPATHY IN T2DM
============================

Diabetic retinopathy (DR), which is one of the chronic diabetes-related vascular complications, is a troublesome complication and significantly increases medical costs \[[@B11][@B12]\]. In Korea, there was a steady increase in the prevalence of DR, from 14.3% in 2006 (*n*=237,267) to 15.9% (*n*=431,964) in 2013 \[[@B13]\]. The prevalence of DR was higher in female patients than in males. The proportion of patients who underwent an annual fundus examination improved from 24.3% in 2006 to 30.0% in 2013. In other words, more than two-thirds of patients with T2DM did not have their fundus checked in a year. However, the proportion of patients with T2DM who received laser treatments or underwent vitrectomy constantly decreased over the last decade. In 2006, among the patients with DR, 2.4% underwent vitrectomy and 11.4% received laser treatments, compared to 1.7% and 6.9%, respectively, in 2013 (*P*\<0.0001) \[[@B13]\]. Accordingly, the percentage of patients with visual impairment who had a best-corrected visual acuity of \<0.1 among DR patients decreased from 2.0% (4,820/237,267) in 2006 to 0.8% (3,572/431,964) in 2013 ([Fig. 1](#F1){ref-type="fig"}) \[[@B13]\].

CARDIOVASCULAR COMPLICATIONS IN T2DM
====================================

A long-standing hyperglycemia, insulin resistance, hypertension, and dyslipidemia cause various metabolic and molecular changes within the myocardium and coronary vessels \[[@B14]\]. These factors play pivotal roles in the development of cardiac dysfunction, diabetic cardiomyopathy, or cardiovascular (CV) disease, although multiple complex mechanisms and contribute to its pathogenesis \[[@B14][@B15]\].

Using the claim DB, six diabetes-related CV complications, including ischemic heart disease, acute myocardial infarction (AMI), ischemic stroke, hemorrhagic stroke, percutaneous coronary intervention, and coronary artery bypass graft, were investigated ([Table 1](#T1){ref-type="table"}). In the population with T2DM over 30 years and older, the age and gender standardized rates of the above six CV outcomes decreased in Korea during the study period. Among them, hospitalization from AMI (−37.3%) and ischemic stroke (−37.0%) dramatically decreased between 2006 and 2013 in T2DM \[[@B16]\]. In the general population without T2DM, hospitalization from hemorrhagic stroke (−29.5%) and ischemic stroke (−28.9%) represented the largest drops. Moreover, the relative decrease in all six CV complications was profound in adults with T2DM compared to those in the general population \[[@B16]\]. But subjects with T2DM continued to show a two- to six-fold higher risk of hospitalization due to major CV complications ([Fig. 2](#F2){ref-type="fig"}) and CV interventions ([Fig. 3](#F3){ref-type="fig"}) than people without T2DM. We suggest this reduced rate of CV outcomes in patients with T2DM seems to be related to the recent trend of improved control rates of hypertension, dyslipidemia, smoking cessation, and glycemic control in T2DM in Korea \[[@B17]\].

DEPRESSION IN T2DM
==================

Previously, the prevalence of depression in patients with T2DM in Korea has been reported as high as 22.6% to 28.8% \[[@B18][@B19]\]. In the analysis using the NHIS DB, depression in T2DM was defined as both T2DM and depression (ICD-10 code of F320-349) with at least one prescription for antidepressants ([Table 1](#T1){ref-type="table"}) \[[@B20]\].

According to the analysis of the NHIS DB from 2003 to 2013, the annual prevalence rates of depression consistently increased both in T2DM and the general population without T2DM ([Fig. 4](#F4){ref-type="fig"}) \[[@B20]\]. During the study period, the prevalence rate of depression in T2DM was about two-fold higher compared to the general population (9.6% vs. 4.6% in 2013). In addition, T2DM patients with depression demonstrated a significantly higher mortality risk than those without depression, especially in males and younger age groups \[[@B20]\]. The 10-year mortality rate in T2DM with depression was 1.4-fold higher compared to T2DM without depression, particularly for those in their 30s and 40s \[[@B20]\].

LIMITATIONS OF THIS ANALYSIS
============================

There are some limitations in this analysis \[[@B5][@B6][@B7]\]. First, because health insurance coverage is confined to the allowable range of the recommendations for antidiabetic drug combinations made by the KHIRA Service in Korea, prescriptions not covered by health insurance were missed in this analysis. In addition, the NHIS DB does not contain uninsured prescriptions or over-the-counter drugs. Second, medical aid (MA) beneficiary information has been incorporated into a single NHIS DB only since 2006; therefore, the NHIS DB included only information on NHIS beneficiaries, not MA beneficiaries, from 2002 to 2005. Third, due to the characteristics of the claim DB, discrepancies between the actual diagnosis and claim data might be possible. Our reported number may not be the actual number of diabetic patients because not every patient who had T2DM visited a clinic or used antidiabetic medication, and not all patients with prescriptions visited the pharmacy and obtained the medication. Fourth, this analysis relied only on claims data; we therefore could not obtain clinical information on glucose or glycosylated hemoglobin levels, diabetic duration, or reasons for nonadherence.

CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS
===========================================

Despite steady improvements in screening, early detection of diabetes, and diabetes care in Korea, the absolute number of patients with T2DM remains high. A large and relevant economic burden remains. Considering the importance of T2DM as a national health issue, the accurate estimation of the use of antidiabetic medications and understanding of diabetes-related complications would be valuable information for the establishment of health policies and the setting of intervention target priorities. Healthcare professionals, academic expert groups such as the KDA, and government agencies should work together to find solutions for the health promotion to Korean patients with T2DM. From this respect, collaborative research by the NHIS and the KDA would be a good first step.

This work was performed with the cooperation of the National Health Insurance Service (NHIS), and the Korean Diabetes Association. The National Health Information Database made by NHIS was used (No. NHIS-2015-4-008).
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###### The operational definitions of type 2 diabetes mellitus and its related comorbidities

![](dmj-42-93-i001)

                                                     Operational definition of diagnosis
  -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type 2 diabetes mellitus from claim DB             ICD-10 code of type 2 diabetes mellitus (E11-E14) as principal diagnosis or up to a fourth additional diagnosis+prescribed at least one antidiabetic drug in a given year
  Type 2 diabetes mellitus from health check-up DB   FBG ≥126 mg/dL (undiagnosed diabetes) or ICD-10 code of type 2 diabetes mellitus with a claim for antidiabetic medication
  Hypertension from claim DB                         ≥1 Claim/year for antihypertensive medication under ICD-10 code of I10-I13, I15
  Dyslipidemia from claim DB                         ≥1 Claim/year for antidyslipidemic agents under ICD-10 code of E78
  Antidiabetic medications                           Sulfonylurea, metformin, DPP-4 inhibitor, alpha-glucosidase inhibitor, meglitinide, thiazolidinedione, insulins
  Diabetic retinopathy                               H36.0
  Panretinal/endolaser photocoagulation              H36.0+S5160^a^/H36.0+S5161^a^
  Pars plana vitrectomy                              H36.0+S5121^a^
  Visual impairment                                  Registered in the National Handicapped Registry
  Ischemic heart disease                             I20-25
  Acute myocardial infarction                        I21-23
  Ischemic stroke                                    I63, I64, I693, I694, G45
  Hemorrhagic stroke                                 I60-62, I690-692
  Percutaneous coronary intervention (PCI)^a^        M6551-2, M6561-4, M6571-2
  Coronary artery bypass graft (CABG)^a^             O1641-2, O6147, OA641-2, OA647
  Depression                                         F32-F34

DB, database; ICD-10, International Classification of Disease 10th revision; FBG, fasting blood glucose; DPP-4, dipeptidyl peptidase-4.

^a^Procedure codes.

###### Prevalence and incidence of type 2 diabetes mellitus from 2006 to 2013
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                        2006         2007         2008         2009         2010         2011         2012         2013
  --------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Claim DB                                                                                                         
   Total population     29,340,486   29,964,692   30,784,595   31,446,745   32,113,334   32,755,158   33,397,816   33,897,232
   Prevalence rate, %   5.6          6.1          6.4          6.8          7.1          7.5          7.8          8.0
    Sex                                                                                                            
     Men                6.0          6.5          6.9          7.4          7.7          8.2          8.5          8.8
     Women              5.3          5.7          6.0          6.3          6.6          6.9          7.1          7.3
   Incidence rate, %    0.95         0.93         0.90         0.91         0.88         0.90         0.83         0.81
    Sex                                                                                                            
     Men                1.07         1.04         1.03         1.02         0.99         1.03         0.97         0.94
     Women              0.84         0.83         0.79         0.80         0.76         0.78         0.71         0.68
  Health check-up DB                                                                                               
   Total population     7,229,856    6,642,441    8,284,141    9,186,594    10,225,856   10,456,856   11,015,182   10,610,669
   Prevalence rate, %   8.4          9.0          8.9          9.9          9.9          10.3         10.5         10.9
    Sex                                                                                                            
     Men                9.2          9.6          9.9          11.0         11.2         11.5         11.9         12.2
     Women              7.3          8.1          7.5          8.5          8.4          8.7          8.8          9.3
   IFG, %               21.5         23.0         22.6         24.2         23.8         23.7         24.0         25.0

DB, database; IFG, impaired fasting glucose.

###### The use of antidiabetic medications (%) among people with diagnosed type 2 diabetes mellitus
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              2002    2003    2004    2005    2006    2007    2008    2009    2010    2011    2012    2013
  ----------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Insulin     8.6     9.5     11.5    14.8    17.3    18.7    19.1    18.6    17.8    17.6    17.3    16.4
  SU          87.2    86.2    85.5    84.3    82.9    81.5    80.0    76.7    70.7    66.2    62.1    58.5
  Metformin   52.9    56.6    59.0    59.7    60.9    62.9    64.9    68.9    72.3    76.9    79.1    80.4
  Glinide     1.0     2.9     3.5     4.1     5.0     6.1     6.3     5.4     4.8     3.6     2.6     2.0
  TZD         7.3     9.4     10.5    11.0    11.5    10.7    11.4    13.0    11.2    8.2     6.6     6.5
  DPP-4i      \-      \-      \-      \-      \-      \-      0.3     8.4     13.9    19.0    28.7    38.4
  α-GI        24.3    24.4    23.0    22.0    23.9    24.4    24.6    22.8    21.4    18.5    13.4    9.4
  Total       181.3   189.0   193.0   196.0   201.5   204.4   206.6   213.7   212.0   210.1   209.8   211.7

SU, sulfonylurea; TZD, thiazolidinedione; DPP-4i, dipeptidyl peptidase-4 inhibitor; α-GI, α-glucosidase inhibitor.
